Posts

GSK seeks to expand Nuvalent lung cancer drug use with new positive data

on

GSK strikes up to $750 million deal for Chimagen blood-cancer therapy

on

GSK to wind down Dresden vaccine factory amid weak flu-vaccine demand

on

GSK’s Ris-Rez cuts death risk by 54% in relapsed small-cell lung cancer trial

on

GSK to license Hutchmed cancer drug for $110 million upfront

on

GSK advances newer mRNA flu-vaccine formulation to Phase 3

on

GSK advances dual-target mRNA flu vaccine to Phase III

on

GSK wins first hepatitis-B approval in Japan

on

Vaccine Makers and Experts Reject Trump’s Push to Split MMR Shot

on

Greg Verdine's LifeMine raises $263M for safer immunosuppressant

on

Relation Deepens GSK AI Pact With Up to $110M Deal Aiming at Transformationally Different Success Rates in Drug Discovery

on

GSK unveils 3‑year cost‑saving plan to fund late‑stage R&D and move research HQ to Cambridge from AZ”,

on

Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout

on

GSK axes key cough drug candidate after mixed Phase 3 data end blockbuster hopes

on

GSK readies global submissions for Jemperli in dMMR/MSI-H rectal cancer

on

Innovent deal seeds Spero’s future beyond GSK’s antibiotic, opening an oncology pipeline in 2026

on

GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win

on

GSK cuts losses on $700M Alzheimer’s pact with Alector after two clinical failures

on

How GSK's new CEO lined up a major buyout to start his time at the top

on

4 years after FDA snub, GSK partnership propels Spero’s Utebzi across approval finish line

on